Kirkland & Ellis Advises on HK$234 Million H-Share Placing for ImmuneOnco Biopharmaceuticals
Kirkland & Ellis advised China International Capital Corporation Hong Kong Securities Limited, the sole global coordinator and placing agent, in the H-share placing (“H-Share Placing”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541). The placement was conducted under the general mandate approved by shareholders earlier this year.
The H-Share Placing, announced on November 21, 2024, and concluded on November 28, 2024, successfully allocated a total of 33,150,000 new H Shares. These shares account for approximately 8.14% of ImmuneOnco Biopharmaceuticals’ expanded issued share capital and were placed with no fewer than six independent investors. The placement generated gross proceeds of approximately HK$234 million for ImmuneOnco Biopharmaceuticals.
ImmuneOnco Biopharmaceuticals is a pioneering biotechnology company focused on advancing immuno-oncology therapies. Setting itself apart on a global scale, the company takes a systematic approach to leverage both the innate and adaptive immune systems, driving innovative solutions in cancer treatment.
Read the announcement
The Kirkland team included corporate/capital markets lawyers Mengyu Lu and Samantha Peng, legal manager Sierra Tao, and international legal consultants Kaiwen Xu and Ashley Guo.
